Skip to main content
Premium Trial:

Request an Annual Quote

Lynx s Revenues Fall, Loss Widens in Q4

NEW YORK, April 1 (GenomeWeb News) - Lynx Therapeutics yesterday reported falling revenues and increased losses for the last quarter of 2003.


Revenues for the quarter fell to $2 million, from $4.7 million for the same quarter in 2002. Lynx attributed this decrease primarily to lower fees for its technology and service, and fewer collaborative research projects.


R&D costs decreased to $2.4 million, down from $4.2 million during the year-ago period.


Lynx's net loss amounted to $3.5 million, or $.65 per share, up from $3 million, or $.69 per share, during the fourth quarter of 2002.


As of Dec. 31, Lynx had cash and cash equivalents of $5.6 million, including $0.7 million in restricted cash.


Click here for the full earnings report.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.